Europe Cancer Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Europe Cancer Vaccines Market is segmented by Technology, Treatment Method (Preventive Vaccine and Therapeutic Vaccine), Application and Geography.

Europe Cancer Vaccines Market Size

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
View Global Report
CAGR
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 10.21 %

Major Players

Europe Cancer Vaccines Market

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Europe Cancer Vaccines Market Analysis

The Europe Cancer Vaccines Market is expected to grow with a CAGR of 10.21% in the forecast period. The key factors propelling the growth of the market is the increasing number of cancer cases, and technological developments in cancer vaccines coupled with huge expenditure on cancer care.

The increasing incidence of cancer has been the major factor for the growth of the European cancer vaccine market. Cancer vaccines play a vital role in the maintenance of the immune system, as they are biological response modifiers. Moreover, healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side effects of the present therapies. Hence, the market for cancer vaccines is expected to grow at a high rate, during the forecast period.

According to the Global Cancer Observatory, the number of new incident cancer cases for the year 2018 was 4.2 million and the deaths exceeded 1.94 million in Europe. Thus, the growing incidence and prevalence of cancer are likely to drive the growth of the cancer therapeutics market in Europe during the forecast period.

Europe Cancer Vaccines Market Trends

This section covers the major market trends shaping the Europe Cancer Vaccines Market according to our research experts:

Preventive Vaccines are Expected to a Hold Significant Market Share in the Treatment Method

Preventive vaccines or prophylactic vaccines are the vaccines intended to prevent cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. The European Medical Authority has approved Gardasil, Gardasil 9, and Cervarix vaccines to protect women from cervical cancer and other HPV-related cancers and pre-cancerous conditions.  

According to GLOBOCAN 2018, report, the number of incident cervical cancer cases in Europe were 61,072 cases and the total number of cancer cases was 56,9847. Therefore as cancer cases are increasing in Europe, the demand for cancer vaccines is expected to increase due to the rising incidence of cancer in the region. Therefore all these factors has helped in the overall market growth.

Europe cancer

Europe Cancer Vaccines Industry Overview

The Europe Cancer Vaccines Market is s highly competitive and consists of a few major players. Companies, like Amgen Inc., OSE Immunotherapeutics, Merck & Co. Inc., Bristol-Myers Squibb, among others, hold substantial shares in the Europe cancer vaccines market.

Europe Cancer Vaccines Market Leaders

  1. Merck & Co. Inc.

  2. Bristol-Myers Squibb

  3. OSE Immunotherapeutics

  4. Amgen Inc.

  5. GlaxoSmithKline PLC

*Disclaimer: Major Players sorted in no particular order

Europe Cancer Vaccines Market.png
Need More Details on Market Players and Competitors?
Download Sample

Europe Cancer Vaccines Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Number of Cancer Cases

      2. 4.2.2 Technological Developments in Cancer Vaccines coupled with Huge Expenditure on Cancer Care

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Guidelines

      2. 4.3.2 Presence of Alternative Therapies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Technology

      1. 5.1.1 Recombinant Cancer Vaccines

      2. 5.1.2 Whole-cell Cancer Vaccines

      3. 5.1.3 Viral Vector and DNA Cancer Vaccines

      4. 5.1.4 Other Technologies

    2. 5.2 By Treatment Method

      1. 5.2.1 Preventive Vaccine

      2. 5.2.2 Therapeutic Vaccine

    3. 5.3 By Application

      1. 5.3.1 Prostate Cancer

      2. 5.3.2 Cervical Cancer

      3. 5.3.3 Other Applications

    4. 5.4 Geography

      1. 5.4.1 Europe

        1. 5.4.1.1 Germany

        2. 5.4.1.2 United Kingdom

        3. 5.4.1.3 France

        4. 5.4.1.4 Italy

        5. 5.4.1.5 Spain

        6. 5.4.1.6 Rest of Europe

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 OSE Immunotherapeutics

      2. 6.1.2 Merck & Co. Inc.

      3. 6.1.3 GlaxoSmithKline PLC

      4. 6.1.4 Bristol-Myers Squibb

      5. 6.1.5 Sanpower Group Co., Ltd.(Dendreon Pharmaceuticals LLC)

      6. 6.1.6 Aduro Biotech, Inc.

      7. 6.1.7 Sanofi SA

      8. 6.1.8 Amgen Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Cancer Vaccines Industry Segmentation

As per the scope of the report, cancer vaccines are defined as the vaccines developed to prevent or treat existing cancers, by strengthening the body's natural immune response system against cancer. These cancer vaccines belong to a class of substances, known as biological response modifiers. These modifiers work by stimulating or restoring the immune system's ability to fight against diseases.

By Technology
Recombinant Cancer Vaccines
Whole-cell Cancer Vaccines
Viral Vector and DNA Cancer Vaccines
Other Technologies
By Treatment Method
Preventive Vaccine
Therapeutic Vaccine
By Application
Prostate Cancer
Cervical Cancer
Other Applications
Geography
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe Cancer Vaccines Market Research FAQs

The Europe Cancer Vaccines Market is projected to register a CAGR of 10.21% during the forecast period (2024-2029)

Merck & Co. Inc., Bristol-Myers Squibb, OSE Immunotherapeutics, Amgen Inc. and GlaxoSmithKline PLC are the major companies operating in the Europe Cancer Vaccines Market.

The report covers the Europe Cancer Vaccines Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Cancer Vaccines Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Nano Radiation Sensors Industry Report

Statistics for the 2024 Nano Radiation Sensors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Nano Radiation Sensors analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Europe Cancer Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)